Antibiotic VRP-034 gets FDA nod for deadly infections
A new antibiotic, VRP-034, has received QIDP status from the US FDA for treating bloodstream infections caused by polymyxin B-susceptible strains. The novel formulation reduces kidney toxicity by up to 70% and retains strong efficacy against drug-resistant bacteria, marking a breakthrough in the fight against antimicrobial resistance.